Woodline Partners LP Altimmune, Inc. Transaction History

Woodline Partners LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$8.22 - $13.81 $1.76 Million - $2.96 Million	214,245 New	214,245 $2.18 Million
Q4 2022 Feb 14, 2023	BUY	$8.74 - $16.45 $2.5 Million - $4.7 Million	285,933 Added 28.09%	1,304,024 $21.5 Million
Q3 2022 Nov 14, 2022	BUY	$10.67 - $22.41 $4.99 Million - $10.5 Million	467,406 Added 84.88%	1,018,091 $13 Million
Q2 2022 Aug 15, 2022	SELL	$3.94 - $11.77 $1.17 Million - $3.48 Million	-295,933 Reduced 34.95%	550,685 $6.44 Million
Q1 2022 May 16, 2022	BUY	$5.9 - $9.45 $1.33 Million - $2.14 Million	225,940 Added 36.4%	846,618 $5.16 Million
Q4 2021 Feb 14, 2022	BUY	$8.69 - $12.48 $2.36 Million - $3.39 Million	271,855 Added 77.93%	620,678 $5.69 Million
Q3 2021 Nov 15, 2021	BUY	$8.43 - $16.81 $2.94 Million - $5.86 Million	348,823 New	348,823 $3.95 Million

190

42M

1.05M

582K

Ticker ALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,025,300
Market Cap $360M
Description
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...

Get notified when there are updates to the investment portfolio of Woodline Partners LP, based on Form 13F filings with the SEC.

Stay updated on Woodline Partners LP with notifications on news.